Given that President Trump is famous for his Earth-shaking tweets, it seems appropriate to comb through Twitter reactions to his administration’s new drug pricing plan, which was unveiled Friday.
Many experts, analysts, and journalists noted the lack of detail in the proposals and the disconnect between Trump’s harsh words against drug makers and pharmacy benefit managers versus how the plan could actually affect industry players. They also pointed out that this plan is just that — any actual changes would need future regulatory moves or congressional action.
Watching the speech now, but on first glance some of the "immediate actions" in the admin's drug pricing proposals are… not immediate. And the "further opportunities" even less so. It's not going to take effect "very soon," as POTUS just said. https://t.co/cY3GBI1qiS
— Rachel Sachs (@RESachs) May 11, 2018
"The drug lobby is making an absolute fortune at the expense of American consumers." Very few of the proposals in the admin's blueprint would materially harm industry.
— Rachel Sachs (@RESachs) May 11, 2018
If you are somehow able to follow through on getting Europe to pay more, this is what happens.
First, US prices stay the same. Next, more drugs come to market because of higher profits. So then, US spending on drugs increases.
— Craig Garthwaite (@C_Garthwaite) May 11, 2018
I see HHS 'may support' some interesting efforts, like updating methods for star ratings to let plans deal more aggressively with high cost drugs, competitive acquisition in part B, indication based pricing. But all tentative, nothing concrete.
— Walid Gellad (@walidgellad) May 11, 2018
They're slamming the PBMs but making them an even bigger, more powerful part of Part D, and giving them a slice of Part B. This is not that bad for them (certainly against expectations). https://t.co/HiYYMhZ1cZ
— Drew Armstrong (@ArmstrongDrew) May 11, 2018
There are quite a few proposals/ideas in Trump's Rx plan, but it is striking how few are actual concrete actions the administration says it will definitely take.
— Noam Levey (@NoamLevey) May 11, 2018
One proposal that caught people’s attention was the idea of requiring drug companies to disclose prices in their advertisements, though there were questions about that as well:
About the Author Reprints
